Page 2 - Torrent Pharma

Street bullish on Torrent Pharma's prospects after in-line Q1 FY26

Analysts are optimistic on Torrent Pharma's growth after a solid Q1 FY26 report, with strong performance in Brazil and US generics despite currency volatility and German challenges

Torrent Pharma Q1 profit rises 20% to ₹548 cr on strong global sales

Torrent Pharmaceuticals on Monday said its consolidated net profit increased 20 per cent year-on-year to Rs 548 crore in the June quarter, driven by strong sales across markets, including India and the US. The drug firm reported a net profit of Rs 457 crore in the April-June quarter of the last fiscal. Revenue from operations rose to Rs 3,178 crore in the June quarter compared with Rs 2,859 crore in the year-ago period, Torrent Pharmaceuticals said in a statement. The drug maker said its India revenues rose by 11 per cent year-on-year to Rs 1,811 crore in the April-June period, led by outperformance in focus therapies. The US business revenues stood at Rs 308 crore in the June quarter, by 19 per cent year-on-year, it added. Similarly, revenue in Brazil rose by 11 per cent to Rs 218 crore, the company stated. Its sales in Germany were up 9 per cent year-on-year to Rs 308 crore in the June quarter against the same period last year. Shares of Torrent Pharma settled 0.75 per cent hi

Torrent Pharma Q1 results: PAT up 20% on robust sales across territories

Torrent Pharmaceuticals reports Rs 548 crore Q1 net profit, led by strong growth in India, the US, and Brazil, with chronic therapies and top brands driving momentum

Top stock picks for July 28: Shyam Metalics, Torrent Pharma; check targets

Stocks to buy: Analyst at Angel One recommends Shyam Metalics and Torrent Pharma; Check target price, stop loss here

Results preview: Pharma firms stare at muted earnings growth for Q1

Indian pharma firms are set to post modest Q1FY26 earnings, with Revlimid erosion impacting US revenues and domestic growth moderating in chronic therapies

Torrent Pharma seeks CCI nod for ₹19,500 cr majority stake in JB Chemicals

Ahmedabad-based Torrent Pharmaceuticals has sought fair trade regulator CCI's clearance to acquire a majority stake in in J B Chemicals and Pharmaceuticals in a Rs 19,500-crore deal. After the completion of the deal, Torrent Pharmaceuticals will become India's second most valued pharma company. The development came after Torrent Pharmaceuticals in June this year announced the acquisition of a majority stake in J B Chemicals and Pharmaceuticals in a Rs 19,500-crore deal. "The proposed combination relates to acquisition of shareholding by the acquirer (Torrent Pharmaceuticals Ltd) in the target (J B Chemicals & Pharmaceuticals Ltd) and the subsequent amalgamation of the target with the acquirer," according to a notice filed with the Competition Commission of India (CCI). Torrent Pharmaceuticals is the flagship company of the Torrent group and is engaged in the business of manufacturing and sale of pharmaceutical formulations (FDFs) across therapeutic segments. J B Chemicals & ...

Brokerages positive on medium-term prospects of Torrent-JB Chemicals merger

Despite steep premium and short-term earnings dilution, analysts expect Torrent Pharma's acquisition of JB Chemicals to be value accretive in the medium term

Torrent Pharma to acquire JB Pharma from KKR at ₹25,689 cr valuation

Torrent Pharma will acquire KKR's 46.39% stake in JB Pharma followed by open offer and merger, strengthening chronic segment and CDMO footprint in India and abroad

Torrent Pharma in advanced talks to acquire JB Chemicals from KKR

Torrent Pharma is negotiating to acquire JB Chemicals from KKR in a deal that may trigger an open offer, strengthening its position in the domestic pharma market

JP Morgan upgrades Torrent Pharma to 'Overweight', lifts target; stk up 5%

Torrent Pharma share price rose after JPMorgan reportedly upgraded the company to 'Overweight'. The brokerage also hiked the target price to ₹3,800, from ₹3,650 earlier.

These 5 pharma stocks can fall up to 12% as technical charts flag caution

Abbott India, Aurobindo Pharma, Cipla, Dr Lal PathLabs and Torrent Pharma flag caution signals on technical charts; here are the key levels to watch out for.

Torrent Pharma Q4 PAT up 11% on strong India biz; Aman Mehta named MD

Torrent Pharma posts Rs 498 crore PAT in Q4FY25; Aman Mehta to become MD from August 1 as part of long-term strategic succession planning by the board

Pharma stocks that you can keep in your portfolio despite US tariff woes

Tausif Shaikh, India analyst for pharma and healthcare, BNP Paribas India, prefers domestic-focused companies like Torrent Pharmaceuticals, and JB Chemicals and Pharmaceuticals in the sector

Alkem Labs, Ipca, Divi's: Three reasons why pharma stocks are falling today

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent

Torrent Pharma Q3 results: PAT rises 14% to Rs 503 cr, misses estimates

The drug maker had reported a profit after tax (PAT) of Rs 443 crore in the October-December quarter of the last fiscal

Nandish Shah of HDFC Securities suggest 'bull spread' on Torrent Pharma

A long build-up is seen in the Torrent Pharma Futures, where we have seen an 18 per cent rise in the open interest with prices rising by 2.5 per cent

Nifty Pharma jumps over 2%: Analysts decode the drivers behind the rally

Individually, Cipla soared up to 3.68 per cent to hit an intraday high of Rs 1,547.70 per share, while Sun Pharma soared up to 3.30 per cent to hit an intraday high of Rs 1,791.60 per share

Torrent Pharma shares gain on USFDA's 'VAI' tag to Pithampur facility

Shares of Torrent Pharmaceuticals rose up to 2.43 per cent to hit an intraday high of Rs 3,180.05 a piece on the BSE

Torrent Pharmaceuticals promoters sell 3% stake, raise Rs 3,087 crore

Torrent Group was actively pursuing the acquisition of Cipla and JB Chemicals and Pharmaceuticals but ultimately withdrew due to high valuations demanded by the sellers

Torrent Investments sells 2.9% stake in Torrent Pharma for Rs 3,086 cr

Torrent Investments, a promoter entity of Torrent Pharmaceuticals, on Wednesday trimmed a 2.9 per cent stake in the company for Rs 3,086 crore through open market transactions. According to the bulk deal data available with the BSE, Torrent Investments Pvt Ltd sold a total of 99.44 lakh shares or 2.94 per cent stake in Torrent Pharmaceuticals. The shares were sold in the price range of Rs 3,103.07-3,104.40 apiece, taking the combined transaction value to Rs 3,086.37 crore. After the stake sale, the combined holding of promoters of Torrent Pharmaceuticals has come down to 68.31 per cent from 71.25 per cent. Details of the buyers of Torrent Pharmaceuticals' shares could not be ascertained on the BSE. Last week, Torrent Pharmaceuticals reported its consolidated profit after tax rose 17 per cent to Rs 453 crore in the September quarter, led by robust sales in the domestic market. The drug firm had reported a profit after tax (PAT) of Rs 386 crore in the July-September period of the l